Clinical trials: Female Osteoporosis
Anorexia Nervosa
Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa
This study seeks to gain new information on why young women with anorexia nervosa are predisposed to early bone loss and osteoporosis.
- Trial name
- NCT00310791
- Testing
- Hormone replacement therapy (estrogen/progestin), Dehydroepiandrosterone (DHEA)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Boston Children's Hospital
Osteoporosis
Intervenous (IV) Zoledronic Acid After Forteo in Postmenopausal Women
The purpose of this study is to evaluate the adequacy of zoledronic acid in maintaining bone mass after two years of treatment with Forteo, in postmenopausal women.
- Trial name
- NCT00361595
- Testing
- zoledronic acid
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- The Cleveland Clinic
Post-Menopausal Osteoporosis
BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.
This single arm study will assess participant preference for monthly Bonviva, versus daily or weekly alendronate or risedronate, in the treatment of postmenopausal osteoporosis.
- Trial name
- NCT00545779
- Testing
- Ibandronate
- Where
- 32 sites in Albania, Bosnia and Herzegovina and 4 more
- Volunteers
- 677 people
- Sponsor
- Hoffmann-La Roche
Post Menopausal Osteoporosis
Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis
To determine the clinical safety and efficacy of abaloparatide transdermal in otherwise healthy postmenopausal women with osteoporosis as assessed by changes in bone mineral density (BMD) and serum markers of bone metabolism when…
- Trial name
- NCT01674621
- Testing
- Abaloparatide Transdermal (50 mcg), Abaloparatide Transdermal (100 mcg), Abaloparatide Transdermal (150 mcg)
- Where
- 9 sites in United States, Denmark and 2 more
- Volunteers
- 250 people
- Sponsor
- Radius Health, Inc.
Low Bone Mineral Density
Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density
To determine the effect of denosumab treatment compared with placebo over 12 months on bone mineral density (BMD) of the lumbar spine in postmenopausal women with low BMD.
- Trial name
- NCT00043186
- Testing
- Denosumab, Alendronate
- Volunteers
- 412 people
- Sponsor
- Amgen
Low Bone Mass, Low Bone Mineral Density
A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab
To characterize the effects of discontinuation of denosumab therapy on variables of bone histology in postmenopausal women with low bone mass or osteoporosis.
- Conditions
- Low Bone Mass, Low Bone Mineral Density, Osteoporosis, Postmenopausal Osteoporosis
- Trial name
- NCT00887965
- Testing
- Previous denosumab
- Volunteers
- 15 people
- Sponsor
- Amgen
Osteoporosis, Postmenopausal
A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal Women
This study is a Phase 1, multi-center, 2-part, subject- and investigator-blind, randomized, placebo-controlled, multiple dose study of transdermal teriparatide (80-µg dose) in healthy postmenopausal women.
- Trial name
- NCT01250145
- Testing
- LY333334
- Where
- 5 sites in United States, Germany and 1 more
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Post-Menopausal Osteoporosis
A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva
This 2 arm study will assess the long-term efficacy and safety of oral treatment with 100mg or 150mg Bonviva in women with post-menopausal osteoporosis who have previously completed Bonviva study BM16549 (MOBILE study).
- Trial name
- NCT00081653
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 31 sites in United States, Belgium and 12 more
- Volunteers
- 719 people
- Sponsor
- Hoffmann-La Roche
Osteoporosis, Postmenopausal
Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis
This is a randomized open label, multi-centre study for Korean women with postmenopausal osteoporosis, evaluating the preference for either the once-monthly dosing of ibandronate or the once-weekly dosing of risedronate.
- Trial name
- NCT00405392
- Testing
- Ibandronate (SB743830HD)
- Volunteers
- 365 people
- Sponsor
- GlaxoSmithKline
Exercise-related Amenorrhea
Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes
One aim of this study is to determine changes in body composition and hormones that differentiate athletes who stop getting their periods versus those who continue to get their periods and non-athletes.
- Trial name
- NCT00946192
- Testing
- Transdermal 17Beta-estradiol, progesterone, Ethinyl Estradiol + Desogestrel
- Where
- United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Low Bone Mineral Density
An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density
An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women with Low Bone Mineral Density
- Trial name
- NCT00325468
- Testing
- AMG 162
- Volunteers
- 200 people
- Sponsor
- Amgen
Post Menopausal Osteoporosis
A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis
This study will evaluate whether an early positive response to once-monthly oral ibandronate in treatment-naive participants with postmenopausal osteoporosis is predictive of efficacy later in treatment.
- Trial name
- NCT02598934
- Testing
- Ibandronate
- Where
- 53 sites in United States, Puerto Rico
- Volunteers
- 308 people
- Sponsor
- Hoffmann-La Roche
Osteoporosis
Viviant 20mg Special Investigation (Regulatory Post Marketing Commitment Plan)
In this survey, to collect the safety and efficacy information of Bazedoxifene in daily medical practice will be examined. In addition, the necessity of special Investigation and post-marketing clinical studies will be examined…
- Trial name
- VIOLINE (NCT01470326)
- Testing
- Bazedoxifene
- Volunteers
- 3,187 people
- Sponsor
- Pfizer
Low Bone Mass, Low Bone Mineral Density
A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With Denosumab
To evaluate the combined effect of denosumab treatment and discontinuation on cortical thickness at the distal radius by High Resolution-Peripheral Quantitative Computed Tomography (HR-pQCT).
- Conditions
- Low Bone Mass, Low Bone Mineral Density, Osteoporosis, Postmenopausal Osteoporosis
- Trial name
- NCT00890981
- Testing
- high-resolution peripheral quantitative computed tomography (HR-pQCT), Dual energy X-ray absorptiometry (DXA), Denosumab
- Volunteers
- 79 people
- Sponsor
- Amgen
Post-Menopausal Osteoporosis
A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment
This 2-arm study was designed to assess the long-term safety and tolerability of intravenous (IV) treatment with 2 mg or 3 mg Bonviva in women with post-menopausal osteoporosis who had previously completed Bonviva study BM16550…
- Trial name
- NCT00551174
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 39 sites in United States, Australia and 13 more
- Volunteers
- 781 people
- Sponsor
- Hoffmann-La Roche
Osteoporosis, Atypical Femoral Fracture
Fracture (FX) Improvement With Teriparatide: FiX-IT Study
This open label comparison study examines the hypothesis that teriparatide given immediately following repair of an atypical subtrochanteric or diaphyseal femoral shaft fracture will enhance healing and improve bone mineral…
- Trial name
- FiX-IT (NCT01705587)
- Testing
- teriparatide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Susan L. Greenspan
Osteoporosis, Age-Related
Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis
The objective of this study was to describe persistence with Prolia® 60 mg administered subcutaneously (SC) every 6 months (Q6M) at 12 and 24 months.
- Trial name
- NCT02732210
- Where
- 89 sites in United States, Canada
- Volunteers
- 935 people
- Sponsor
- Amgen
Hereditary Breast and Ovarian Cancer Syndrome, Osteoporosis
Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries
This randomized phase II trial is studying zoledronate to see how well it works compared to observation in maintaining bone mineral density in patients who are undergoing surgery to remove both ovaries.
- Conditions
- Hereditary Breast and Ovarian Cancer Syndrome, Osteoporosis, Ovarian Carcinoma
- Trial name
- NCT00305695
- Testing
- Laboratory Biomarker Analysis, Zoledronic Acid
- Where
- 95 sites in United States
- Volunteers
- 160 people
- Sponsor
- Gynecologic Oncology Group
Osteoporosis
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women
The primary objective was to evaluate the safety and tolerability of denosumab (AMG 162) after a single subcutaneous administration in Japanese postmenopausal women.
- Trial name
- NCT03822078
- Testing
- Denosumab
- Volunteers
- 45 people
- Sponsor
- Amgen
Postmenopausal Women With Osteoporosis
Effect of Stopping Risedronate After Long Term Treatment on Bone Turnover
The effects of stopping long-term (7 years) and short term (2 years) risedronate therapy on BMD (bone mineral density) and BTMs (bone turnover markers) will be summarized.
- Trial name
- NCT01249261
- Testing
- Risedronate
- Where
- 13 sites in Australia, Belgium and 6 more
- Volunteers
- 61 people
- Sponsor
- Warner Chilcott